

Effect of Frequent Self-Monitoring of Blood Glucose on HbA1c Level Among Type 2 Diabetic Patients

¹Selwa Elias Yacoub, ²Miaad Hana Mansur and ¹Yousif Abdul Raheem

¹Department of Community Medicine,

Al Kindy College of Medicine, University of Baghdad, Baghdad, Iraq

²Specialization Center of Endocrinology and Diabetes, University of Baghdad, Baghdad, Iraq

Abstract: Self-Monitoring of Blood Glucose (SMBG) is an integral part of management of type 2 diabetes mellitus on insulin and oral agents. SMBG is an important adjunct to HbA1c which is a standard assessment of glycemia. To evaluate the effectiveness of frequent use of SMBG on the level of HbA1c among type 2 diabetic patients. A cross sectional study had been conducted at the specialized Center of Endocrinology and Diabetes for the period from October 2009 till August 2010. A convenient sample of 126 type 2 diabetic patients attending the center had been enrolled. The participants were classified into 3 groups according to the frequency of using SMBG, the demographic characteristic, Body Mass Index (BMI), duration of diabetes mellitus, line of treatment and the mean level of HbA1c of all participants had been assessed. No statistical differences had been found in the demographic characteristic, BMI duration of diabetes mellitus, line of treatment and the mean level of HbA1c among the three studied groups. Participants of secondary and higher education were more frequently use SMBG. Neither Patients on oral hypoglycemic drugs nor those on a regimen include insulin show differences in their HbA1c in relation to frequency of SMBG use. Use of SMBG regardless of its frequency among type 2 diabetic patients was not beneficial to achieve a better glycemic control as monitored by the level of HbA1c, optimization of its effectiveness may require advanced facility for better interpretation and response adapted by the patients and doctors.

Key words: SMBG, HbA1c, type 2 diabetes mellitus, glycemic control, patients, Iraq

INTRODUCTION

Diabetes is a significant and growing worldwide health concerns. People with diabetes are at increased risk for developing numerous complications resulting in increased health care costs. Blood glucose control is critical for managing diabetes and to reduce the development and/or progression of microvascular and macrovascular complications (Parkin and Davidson, 2009; Davis *et al.*, 2006).

The American Diabetes Association recommends Self-Monitoring (SMBG) as an integral part of diabetes management for patients who are treated with insulin and as a useful component for achieving glycemic goals for patients use oral medications or medical nutrition (American Diabetes Association, 2007) in addition patients with diabetes should have a glycated hemoglobin (HbA1c) measurement at least two times a year (American Diabetes Association, 2007) so both measurements are essential for standard assessment of glycemic control (American Diabetes Association, 2002; Palmer *et al.*, 2006).

All diabetic patients attending SCED taught to use SMBG as part of the educational program adapted by the center and their HbA1 mostly measured every 6 months.

HbA1c reflects mean blood glucose levels in over the previous 2-3 months (Derr *et al.*, 2003). While Self assessment of Blood Glucose (SMBG) provides information immediately on the actual blood glucose levels at the time of testing (Palmer *et al.*, 2006) and permits the well informed and motivated patients to make appropriate adjustments in treatment (particularly in insulin dose) on a day to day basis. It also reveal patterns of changes in blood glucose throughout the day and document hypo or hyperglycemia (American Diabetes Association, 2002).

Self Monitoring of Blood Glucose (SMBG) has become a principle component of diabetes management particularly in insulin treated patients (Parkin and Davidson, 2009) though its efficacy independent of other self management practices is still uncertain (Adams *et al.*, 2003) and no studies either experimental or observational have addressed the long term impact of various SMBG testing frequencies on glycemic control (Karter *et al.*, 2006).

This study had been conducted to explore the beneficial effect of frequent use of SMBG on glycemic control among Type 2 diabetes revealed by its relevance to the level of HbA1c.

MATERIALS AND METHODS

A cross sectional study had been conducted at the Specialized Center of Endocrinology and Diabetes (SCED) in Baghdad for the period from October 2009 till August 2010. A convenient sample of 126 diabetic patients attending this center were enrolled.

Inclusion criteria:

- Type 2 diabetes mellitus
- Registered at the SCED for at least 6 months ago
- Being restricted to the specified line of treatment for the last 6 months
- Initiate using SMBG at least 6 months prior to the time of participation in the study (for SMBG user's)
- Can recall the frequency of using SMBG

All participants had completed through an interview, a unique questioner to address their age, sex, educational status, duration of Diabetes Mellitus (DM) and line of treatment. Patients were defined according to their educational status into three levels, primary, secondary and higher education.

Initially stratification of the studied sample was done according to the line of treatment into 3 strata; no medication (diet controlled only), Oral Hypoglycemic Drug (OHD) and insulin (either alone or any other regimen that includes insulin) (Karter *et al.*, 2006).

The frequency of using SMBG had been assessed depending on the recall information of practicing it during the last 6 months before the interview and accordingly the participants were classified into 3 main studied groups; group 1 using it one or more times per week, group 2 <1 time week⁻¹ and group 3 never use it (Davis *et al.*, 2006).

Duration of Diabetes Mellitus (DM) was calculated in years (the lowest duration being 1/2 year) and accordingly the included patients were divided into 3 categories; <5 years between 5-10 years and >10 years duration.

Anthropometric measurements had been done for each patient, weight measured with their indoor clothing using a digital weight scale (Seca, Austrialia) and calculated to the nearest fraction of kg while height was measured in standing position without shoes using CMS weighing equipment LTD. Body Mass Index (BMI) then calculated by dividing weight (kg) by height (m²).

Level of HbA1c had been measured for all the participants being achieved by the laboratory of SCED using liquid chromatography. All data was introduced into a personal computer and analyzed using Minitab version 13, χ^2 -test was used for interpretation of discrete data while ANOVA test was applied for mean analysis of continuous data. The p<0.05 was the level of significance in this study.

RESULTS AND DISCUSSION

Among 126 diabetic patients participating in this study (Table 1) being classified according to the frequency of using SMBG into three main groups, 64 (50.80%) were in group 1 using it one or more times weekly, 28 (22.22%) found to be in group 2 using it less than one time weekly and 34 (26.98%) were in group 3 never using it. An overall users of 92 (72.02%) patients.

No significant statistical differences had been found in the demographic characteristic of the patients among the three groups regarding their gender (p = 0.455), mean age (p = 0.054) and mean BMI (p = 0.957). The only statistical differences found to be related to their educational level (p = 0.008).

Table 1: Demographic characteristic, BMI, duration of D.M, line of treatment and level of HbA1c in relation to frequency of using SMBG

Variables	Frequency of SMBG			Total n = 126	p-value
	Group 1* n = 64	Group 2** n = 28	Group 3*** n = 34		
Male	29.000	16.000	19.000	64.000	-
Female	35.000	12.000	15.000	62.000	0.455
Age					
Mean	42.440	36.570	45.290	41.580	-
SD	14.480	12.000	15.260	13.480	0.054
Min.	18.000	20.000	19.000	18.000	-
Max.	78.000	68.000	81.000	81.000	-
Education					
Primary	12.000	9.000	13.000	34.000	-
Secondary	26.000	16.000	16.000	58.000	0.008
Higher	26.000	3.000	5.000	34.000	-
BMI					
Mean	27.080	27.030	27.370	27.050	-
SD	5.129	6.560	4.440	4.970	0.957
Min.	16.300	18.600	20.300	16.300	-
Max.	40.440	37.500	36.250	40.440	-
Duration of DM (years)					
<5	16.000	8.000	12.000	36.000	0.865
5-10	26.000	11.000	11.000	48.000	-
>10	22.000	9.000	11.000	42.000	-
Treatment					
OHD	12.000	7.000	9.000	28.000	-
Insulin†	52.000	21.000	25.000	98.000	0.629
HbA1c 1					
Mean	6.622	7.164	6.865	7.013	-
SD	1.192	1.290	1.307	1.231	0.551
Min.	4.900	5.800	4.900	4.900	-
Max.	10.000	10.500	9.400	10.500	-

*One or more times week⁻¹; **Less than one time week⁻¹; ***Never use; † Insulin or any other regimen include insulin

Table 2: Mean level of HbA1c in association to the frequency of SMBG and educational level

Level of education	Frequency of SMBG			p value
	Group 1 n = 64	Group 2 n = 28	Group 3 n = 34	
Primary				
No	12.000	9.000	13.000	-
HbA1c 1				
Mean	7.050	7.367	6.975	-
SD	1.746	1.577	0.754	0.389
Secondary				
No	26.000	16.000	16.000	-
HbA1c 1				
Mean	6.625	6.714	6.880	-
SD	0.948	0.267	1.197	0.974
Higher				
No	26.000	3.000	5.000	-
HbA1c 1				
Mean	6.463	6.238	6.713	-
SD	1.128	0.858	1.441	0.541
pvalue	0.376	0.046	0.931	-

The three groups showed no differences in relation to the duration of D.M ($p = 0.865$). Non of the participants found to be assigned to medical diet alone as one of the lines of treatment of type 2 diabetes and ultimately 2 subdivision only had been identified, 28 (22.22%) receiving Oral Hypoglycemic Drug (OHD) and 98 (77.78%) found to be on insulin (either alone or any other regimen that includes insulin), no differences had been found between the main three studied groups in relation to their line of treatment ($p = 0.629$).

The mean level of HbA1c did not reveal any statistical differences between the three studied groups in association to the frequency of using SMBG ($p = 0.551$).

The only significant statistical differences in the level of within the three main groups of the studied sample considering their educational level (Table 2) found within group 2 (using SMBG <1 times weekly) ($p = 0.046$) while no significant differences was found in between them accordingly.

No significant differences was found in the mean level of HbA1c in between participants of the three groups (Table 3) in relation to the duration of DM, the only significant differences ($p = 0.005$) within group 2, those using SMBG less than once weekly.

The three main studied groups show no statistical differences in the mean level of HbA1c (Table 4) in between or within them in relation to the line of treatment being on OHD or on insulin containing regimen.

The utility of SMBG reported by 72.03% of type 2 diabetic patients in the present sample found to be similar to the results of a Fermental diabetes study conducted at Austeralia 2006 (Davis *et al.*, 2006) being 70%, revealing the awareness among diabetic patients attending the SCED to the importance of individual monitoring of blood glucose and addressing the availability and affordability

Table 3: Mean level of HbA1c in association to frequency of SMBG and duration of DM

Duration DM (years)	Frequency of SMBG			p value
	Group 1 n = 64	Group 2 n = 28	Group 3 n = 34	
<5				
No	16.000	8.000	12.000	-
HbA1c 1				
Mean	6.518	6.740	6.829	-
SD	1.027	0.704	1.383	0.546
5-10				
No	26.000	11.000	11.000	-
HbA1c 1				
Mean	6.682	8.429	6.844	-
SD	1.505	1.946	1.346	0.950
>10				
No	22.000	9.000	11.000	-
HbA1c 1				
Mean	6.944	6.714	6.840	-
SD	1.267	0.267	1.081	0.901
p-value	0.617	0.005	0.982	-

Table 4: Mean level of HbA1c in association with frequency of SMBG and line of treatment

Line of treatment	Frequency of SMBG			p value
	Group 1 n = 64	Group 2 n = 28	Group 3 n = 34	
OHD				
No	12.000	7.000	9.000	0.86
HbA1c				
Mean	6.660	6.860	6.580	-
SD	0.940	0.950	1.330	-
Insulin				
No	52.000	21.000	25.000	0.73
HbA1c				
Mean	6.790	7.270	6.780	-
SD	1.470	1.530	1.560	-
p-value	0.714	0.570	0.862	-

of glucose meters and strips for them. Also it may reflect the strategy of using SMBG as part of usual care and one of the practices encouraged through health education program implemented to achieve glycemic control in this center.

Neither gender nor age found to be related to the frequency of SMBG utilization while in a study of >44 managed care patients with type 1 and type 2 DM, Karter *et al.* (2000) identified older age, male gender as independent predictors of less frequent self monitoring in diabetic patients, might be explained by the differences in the attitude and motivation provided for diabetic patients among different societies toward using SMBG.

Lower rates of SMBG were correlated with having less than secondary or higher education found to be consistent with findings from other studies, the negative association between SMBG and lower education suggest that socioeconomic barriers might impede the practice of SMBG (Harris *et al.*, 1993; Adams *et al.*, 2003).

In a study conducted in eastern Massachusetts in Boston, Adams *et al.* (2003) conclude that insulin

managed patients were more likely to self monitor compared to those using oral medications which was not evident in the present study since SMBG reported by the interviewer might be underestimated or overestimated since it subjected to recall bias.

The aim of using SMBG is to improve glycemic control to lower HbA1c and ultimately reduced long term complications (Martin *et al.*, 2006), the similarity in the mean level of HbA1C among participants in this study associated with frequency of SMBG and regardless of the line of treatment among type 2 diabetes which was also evident in other studies Both cross-sectional and longitudinal fermantle diabetes study (Davis *et al.*, 2006) showed that HbA1c was not significantly different between SMBG users and non users, neither SMBG testing nor it's frequency was associated with glycemic benefits in type 2 diabetes patients regardless of treatment (Davis *et al.*, 2006) on the other hand a prospective randomized controlled trial in Ireland (ESMON study) (O'Kane *et al.*, 2008) concluded that SMBG in people with newly diagnosed type 2 diabetes gave no advantage in improvement in glycemic control compared with those did not monitor (O'Kane *et al.*, 2008). While benefits of SMBG in the management of patients with type 2 diabetes not receiving insulin have been observed in the Kaiser Permanent Northern California Medical Care Program and the ROSSO study (Martin *et al.*, 2006; Kolb *et al.*, 2007) and in a meta analysis study of 1307 non insulin treated patients with type 2 diabetes demonstrated a 0.42% lower HbA1c level in those patients who performed SMBG as compared to those who did not apply (Schnell and Heinemann, 2007).

Although, many studies have reported negative findings regarding SMBG in non insulin treated diabetes (Parkin and Price, 2007; Davidson *et al.*, 2005), optimal SMBG use requires that both patients and health care professionals monitor, interpret and respond appropriately to acute glucose excursions and patterns of glycemia identified through SMBG (Parkin and Price, 2007; Klonoff, 2008; Austin *et al.*, 2006).

Failure to have benefit from SMBG use in non-insulin treated diabetes may stem from a misapplication or misunderstanding of true utility of SMBG as a tool to guide therapy rather than an independent therapeutic intervention (Parkin and Price, 2007; Klonoff, 2008; Parkin and Hirsch, 2005).

The key to effective use of SMBG in clinical practice is pattern analysis which is a systematic approach to identifying glycemic patterns within SMBG data and when taking appropriate action based upon those results (Dailey, 2007), the availability of computer based and paper based data collection and management tools

facilitates more robust and efficient use of SMBG data allowing clinicians and patients to quickly identify glycemic patterns and make more informed decisions about therapeutic adjustments that may be required (Parkin and Davidson, 2009).

CONCLUSION

SMBG remains one of effective and easily handled tool that reflect the awareness of diabetic patients toward the sequel of uncontrolled hypeglycemia. To optimize the benefit of utilizing SMBG and to render it to a cost benefit regimen requires intensified diabetes education program carried by the specialized centers of diabetes to lead the patients for the optimal timing and frequency of self monitoring and how to interpret and response to the results correctly by precise adjustment of their diet, exercise and medicine. Such programs can be followed by further studies to monitor the effectiveness of SMBG.

REFERENCES

- Adams, A.S., C. Mah, S.B. Soumerai, F. Zhang, M.B. Barton and D. Ross-Degnan, 2003. Barriers to self-monitoring of blood glucose among adults with diabetes in an HMO: A cross sectional study. *BMC Health Services Res.*, 3: 6-6.
- American Diabetes Association, 2002. Clinical practice recommendations 2001: Standards of medical care for patients with diabetes. *Diabetes Care*, 24: 533-550.
- American Diabetes Association, 2007. Standards of medical care in diabetes-2007. *Diabetes Care*, 30: 4-41.
- Austin, M.M., L. Haas, T. Johnson, C.G. Parkin, C.L. Parkin, G. Spollett and M.T. Volpone, 2006. Self-monitoring of blood glucose: Benefits and utilization. *Diabetes Educ.*, 32: 835-836-844-847.
- Dailey, G., 2007. Assessing glycemic control with self-monitoring of blood glucose and hemoglobin A(1c) measurements. *Myo Clin. Proc.*, 82: 229-235.
- Davidson, M.B., M. Castellanos, D. Kain and P. Duran, 2005. The effect of self monitoring of blood glucose concentrations on glycated hemoglobin levels in diabetic patients not taking insulin: A blinded, randomized trial. *Am. J. Med.*, 118: 422-425.
- Davis, W.A., D.G. Bruce and T.M. Davis, 2006. Is self-monitoring of blood glucose appropriate for all type 2 diabetic patients: The fremantle diabetes study. *Diabetes Care*, 29: 1764-1770.
- Derr, R., E. Garrett, G.A. Stacy and C.D. Saudek, 2003. Is HbA1c affected by glycemic instability. *Diabetes Care*, 26: 2728-2733.

- Harris, M.I., C.C. Cowie and L.J. Howie, 1993. Self-monitoring of blood glucose by adults with diabetes in the United States population. *Diabetes Care*, 16: 1116-1123.
- Karter, A.J., A. Ferrara, J.A. Darbinian, L.M. Ackerson and J.V. Selby, 2000. Self-monitoring of blood glucose: Language and financial barriers in a managed care population with diabetes. *Diabetes Care*, 23: 477-483.
- Karter, A.J., M.M. Parker, H.H. Moffet, M.M. Spence, J. Chan, S.L. Ettner and J.V. Selby, 2006. Longitudinal study of new and prevalent use of self-monitoring of blood glucose. *Diabetes Care*, 29: 1757-1763.
- Klonoff, D.C., 2008. New evidence demonstrates that self-monitoring of blood glucose does not improve outcomes in type 2 diabetes-when this practice is not applied properly. *J. Diabetes Sci. Technol.*, 2: 342-348.
- Kolb, H., B. Schneider, L. Heinemann, V. Lodwig, W.A. Scherbaum and S. Martin, 2007. Altered disease course after initiation of self-monitoring of blood glucose in noninsulin-treated type 2 diabetes (ROSSO 3). *J. Diabetes Sci. Technol.*, 1: 487-495.
- Martin, S., B. Schneider, L. Heinemann, V. Lodwig and H.J. Kurth *et al.*, 2006. Self-monitoring of blood glucose in type 2 diabetes and long-term outcome: An epidemiological cohort study. *Diabetologia*, 49: 271-278.
- O'Kane, M.J., B. Bunting, M. Copeland, V.E. Coates and ESMON Study Group, 2008. Efficacy of self monitoring of blood glucose in patients with newly diagnosed type 2 diabetes (ESMON study): Randomised controlled trial. *Br. Med. J.*, 336: 1174-1177.
- Palmer, A.J., S. Dinneen, J.R. Gavin, A. Gray, W.H. Herman and A.J. Karter, 2006. Cost-utility analysis in a UK setting of self-monitoring of blood glucose in patients with type 2 diabetes. *Curr. Med. Res. Opin.*, 22: 861-872.
- Parkin, C.G. and D. Price, 2007. Randomized studies are needed to assess the true role of self-monitoring of blood glucose in noninsulin-treated type 2 diabetes. *J. Diabetes Sci. Technol.*, 1: 595-602.
- Parkin, C.G. and I.B. Hirsch, 2005. Self-monitoring of blood glucose cannot compensate for ineffective diabetes management. *Am. J. Med.*, 118: 1448-1449.
- Parkin, C.G. and J.A. Davidson, 2009. Value of self-monitoring blood glucose pattern analysis in improving diabetes outcomes. *J. Diabetes Sci. Technol.*, 3: 500-508.
- Schnell, O. and L. Heinemann, 2007. Self-monitoring of blood glucose in noninsulin-treated patients with type 2 diabetes: A never ending story. *J. Diabetes Sci. Technol.*, 1: 614-616.